Kasra Karamlou, MD
Hematology & Oncology · Sandusky, OHNPI 1548263163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,542,637 of the $1,781,365 with a category attached, or 86.6%. It is spread thinly across 52 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2021 at $388,915 and has fallen 68.2% since, to $123,781 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,238 payments — averaging $1438.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$362K
- Incyte Corporation$213K
- Beigene USA, Inc.$209K
- AstraZeneca$149K
- Takeda Pharmaceuticals U.S.A., Inc.$121K
- Amgen$110K
- plus $617K from 46 others
Across 83 payments — averaging $2227.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$58K
- Pfizer$41K
- AstraZeneca$28K
- Genentech, Inc.$24K
- Eli Lilly$19K
- Pharmacyclics LLC, An Abbvie Company$10K
- plus $6K from 3 others
What the payments were for
- Consulting fees$110,0336%
- Speaking & faculty fees$1,542,63787%
- Travel & lodging$101,0826%
- Food & beverage$25,9091%
- Education$1,7040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,781,365 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 47 | $690,327 |
| PomalystPomalidomide | 27 | $576,968 |
| JakafiRuxolitinib Phosphate | 41 | $575,558 |
| FruzaqlaFruquintinib | 20 | $482,216 |
| RevlimidLenalidomide | 25 | $429,550 |
| CabometyxCabozantinib S-Malate | 21 | $415,355 |
| ImbruvicaIbrutinib | 19 | $333,406 |
| Lenalidomide | 25 | $288,296 |
| VerzenioAbemaciclib | 14 | $214,095 |
| BosulifBosutinib | 12 | $212,968 |
| ScemblixAsciminib Hydrochloride | 12 | $156,918 |
| EliquisApixaban | 51 | $43,902 |
| Abiraterone Acetate | 27 | $40,776 |
| Imatinib Mesylate | 12 | $31,902 |
| Ondansetron Hcl | 64 | $2,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $209,346 | $690,32747 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $362,247 | $576,96827 claims |
| Incyte CorporationJakafi | $213,314 | $575,55841 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $120,785 | $482,21620 claims |
| Bristol Myers SquibbRevlimid | $34,665 | $429,55025 claims |
| Exelixis Inc.Cabometyx | $99 | $415,35521 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $2,221 | $333,40619 claims |
| PfizerBosulif, Eliquis | $45 | $256,87063 claims |
| Lilly USA, LLCVerzenio | $84 | $214,09514 claims |
| NovartisScemblix | $29 | $156,91812 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $40 | $40,77627 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $19 | $83540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Sandusky
- Hillard LazarusCleveland$2M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
- Hetty CarrawayChagrin Falls$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.